TY - JOUR
T1 - Contribution of cortical lesions to cognitive impairment in Japanese patients with multiple sclerosis
AU - Shinoda, Koji
AU - Matsushita, Takuya
AU - nakamura, yuri
AU - Masaki, Katsuhisa
AU - Sakai, Shiori
AU - Nomiyama, Haruka
AU - Togao, Osamu
AU - Akio, Hiwatashi
AU - Niino, Masaaki
AU - Isobe, Noriko
AU - Kira, Jun-Ichi
N1 - Funding Information:
This study was supported in part by the following grants: a research grant from the Japan Intractable Disease Research Foundation; a Health and Labour Sciences Research Grant on Intractable Diseases (H26-Nanchitou (Nan)-Ippan-043) from the Ministry of Health, Labour and Welfare, Japan; a Grant-in-Aid for Scientific Research A (MEXT KAKENHI Grant No. 16H02657) and C (15K09341); and a Grant-in-Aid for Young Scientists B (17K16125) from the Japan Society for the Promotion of Science, Japan. We thank Doran Amos, PhD, and Rebecca Tollefson, DVM, from Edanz Group (https://en-author-services.edanzgroup.com/) for editing drafts of this manuscript.
Funding Information:
K.S. received speaker honoraria from Biogen Idec Japan and Takeda Pharmaceutical Company. T.M. received a grant and payment from Bayer Schering Pharma and Takeda Pharmaceutical Company for manuscript preparation and development of educational presentations and also received speaker honoraria payments from Mitsubishi Tanabe Pharma, Bayer Schering Pharma, and Biogen Idec Japan. Y.N. received grant support from Mitsubishi Tanabe Pharma, Bayer Yakuhin, Ltd., and Japan Blood Products Organization and also received speaker honoraria from Novartis Pharma. M.N. has received speaker honoraria from Biogen Idec Japan, Novartis Pharma, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, and Alexion Pharma Godo Kaisha. N.I. received grant support from Mitsubishi Tanabe Pharma, Osoegawa Neurology Clinic, Bayer Yakuhin, Ltd., and Japan Blood Products Organization. J.K. received grants from the Ministry of Health, Labour, and Welfare, Japan; the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Japan Society for the Promotion of Science; and the Japan Agency for Medical Research and Development (AMED), Japan. J.K. further received grants and personal fees from Biogen Idec Japan, Novartis Pharma, Philips and Mitsubishi Tanabe Pharma, Eisai, Otsuka Pharmaceutical, Chugai Pharmaceutical Company, Nihon Pharmaceutical Company, and Fukuda Denshi. K.M., S.S., H.N., O.T., and A.H. have nothing to declare.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Cortical lesions (CLs) have a low prevalence and are associated with physical disabilities in Japanese patients with multiple sclerosis (MS). However, the contribution of CLs to cognitive impairment remains unclear in Asian MS. Sixty-one prospectively enrolled MS patients underwent three-dimensional double inversion recovery MR imaging, the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), the Apathy Scale (AS), the Fatigue Questionnaire (FQ), and the Hospital Anxiety and Depression Scale (HADS) within a 1-week period. The cognitive impairment index (CII) score was calculated to measure patients’ overall cognitive impairment. MS patients with CLs had poorer scores than those without CLs in most BRB-N tests, but scored comparably in the FQ, AS, and HADS. The number of CLs correlated negatively with all BRB-N test scores and positively with total CII scores. Leukocortical lesions were more extensively associated with cognitive dysfunction in various domains than intracortical lesions. Stepwise multiple regression analysis revealed that potential confounding factors for the highest quartile of CII score were the number of CLs (odds ratio 2.38, p = 0.0070) and the Expanded Disability Severity Scale score (odds ratio 2.13, p = 0.0003). Our results demonstrate that the presence and number of CLs are robustly associated with cognitive dysfunction in Asian MS patients.
AB - Cortical lesions (CLs) have a low prevalence and are associated with physical disabilities in Japanese patients with multiple sclerosis (MS). However, the contribution of CLs to cognitive impairment remains unclear in Asian MS. Sixty-one prospectively enrolled MS patients underwent three-dimensional double inversion recovery MR imaging, the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), the Apathy Scale (AS), the Fatigue Questionnaire (FQ), and the Hospital Anxiety and Depression Scale (HADS) within a 1-week period. The cognitive impairment index (CII) score was calculated to measure patients’ overall cognitive impairment. MS patients with CLs had poorer scores than those without CLs in most BRB-N tests, but scored comparably in the FQ, AS, and HADS. The number of CLs correlated negatively with all BRB-N test scores and positively with total CII scores. Leukocortical lesions were more extensively associated with cognitive dysfunction in various domains than intracortical lesions. Stepwise multiple regression analysis revealed that potential confounding factors for the highest quartile of CII score were the number of CLs (odds ratio 2.38, p = 0.0070) and the Expanded Disability Severity Scale score (odds ratio 2.13, p = 0.0003). Our results demonstrate that the presence and number of CLs are robustly associated with cognitive dysfunction in Asian MS patients.
UR - http://www.scopus.com/inward/record.url?scp=85082510201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082510201&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-61012-3
DO - 10.1038/s41598-020-61012-3
M3 - Article
C2 - 32251297
AN - SCOPUS:85082510201
SN - 2045-2322
VL - 10
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 5228
ER -